Business Wire·Nov 7, 2026, 4:15 PM ET

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

ARWR

Pooled SHASTA-3 & SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall & 91% in sHTG patients with recent pancreatitis history versus placebo.
PALISADE open-label extension demonstrated sustained triglyceride & APOC3 reductions for up to 36 months in FCS patients, with median reductions of 76% & 89% respectively.
Single doses of investigational ARO-DIMER-PA produced mean LDL-C reductions of 26% to 65% & median triglyceride reductions of 56% to 78% in mixed hyperlipidemia patients.
ARO-DIMER-PA also achieved mean PCSK9 reductions of 50% to 89%, APOC3 reductions of 43% to 95%, ApoB reductions of 32% to 66%, & remnant cholesterol reductions of 52% to 73%.
SHASTA-3 & SHASTA-4 pooled data identified recent acute pancreatitis history as a key risk marker, with event rates reduced by 82% in patients with prior pancreatitis & baseline TGs of 500-880 mg/dL.
Safety data for plozasiran in SHASTA-3/4 showed treatment-emergent adverse events in 73% of patients, with worsening glycemic control reported in 14% of the plozasiran group.
PALISADE extension reported three adjudicated acute pancreatitis events, increased HbA1c in 8% of patients, & one death due to cardiac arrhythmia assessed as unrelated to treatment.
ARO-DIMER-PA Phase 1/2a interim results indicated injection-site erythema was the most common adverse event, occurring in 20 of 21 treated participants, with no serious adverse events or deaths reported.
Arrowhead Pharmaceuticals presented these cardiometabolic RNAi therapies at the American Heart Association Scientific Sessions 2026 in Chicago.
The company stated ARO-DIMER-PA utilizes its TRiM platform to target two genes simultaneously, aiming to address both LDL cholesterol & triglyceride-rich lipoproteins.